Figures & data
a, The dotted line shows a TLS in CRC tissue (magnification, x200). The slide was stained with CD3 (yellow), CD8 (green), CD20 (purple), FDC (white), CD68 (pink), Bcl-6 (red), and DAPI (blue). Scale bar, 100 µm. b, A TLS displayed separately by each antigen with DAPI. Scale bar, 100 µm. TLS, tertiary lymphoid structure; CRC, colorectal cancer
a, Comparisons of numbers of TLSs per 100 mm2 tumor area between two patient groups, divided by age (<65 years, n = 24; ≥65 years, n = 43), pathological stage (stage II, n = 22; stage III, n = 45), side of the primary tumor (right side, n = 26; left side, n = 41), and disease relapse after surgery (no recurrence (No Rec), n = 54; recurrence (Rec), n = 13). b, Comparisons of proportions of cellular components of TLSs between patients without and with disease relapse (no recurrence, n = 47; recurrence, n = 11). Each component is defined as: B cell (CD20+Bcl-6-), Helper T cell (CD3+CD8-Bcl-6-), FDC (FDC+), CTL (CD3+CD8+), macrophage (CD68+), Tfh (CD3+CD8-Bcl-6+), and GC B cell (CD20+Bcl-6+). In both a and (b), P values were calculated by the Wilcoxon rank-sum test. Dots indicate mean values of each patient. Box plots show the median and first and third quartiles, and whiskers extend to 1.5 times the interquartile range of the patient groups. TLS, tertiary lymphoid structure; FDC, follicular dendritic cell; CTL, cytotoxic T lymphocyte; Tfh, follicular helper T cell; GC, germinal center
a, Comparisons of proportions of Th cell subsets between patients with lower densities of Th (Th<34.1%) and those with higher densities (Th≥34.1%) (Th low, n = 28; Th high, n = 7). Each subset is defined as: Th1 (CD3+T-bet+), Th2 (CD3+GATA3+), Th17 (CD3+ROR-γT+), and Treg (CD3+FOXP3+). Dots indicate mean values of each patient. Box plots show the median and first and third quartiles, and whiskers extend to 1.5 times the interquartile range of the patient groups (a,c). P values were calculated by the Wilcoxon rank-sum test (a,c). b, Scatter plot for the proportions of Th cells and CD3+GATA3+ Th2 cells in 35 patients. Correlation coefficients and P values were calculated using Pearson’s correlation coefficient analysis. c, Comparison of proportions of Th2 between patients without and with disease relapse (no recurrence, n = 28; recurrence, n = 7). d, Representative image of TLS in a Th-high patient. The dotted line encircles a TLS in CRC tissue (magnification, x200). Slides were stained with CD3 (yellow), T-bet (cyan), GATA3 (red), ROR-γT (green), FOXP3 (pink), and DAPI (blue). The percentages were calculated as the numbers of CD3+CD8-Bcl-6- (Th) and CD3+GATA3+ (Th2) per all nucleated cells in a TLS. Scale bar, 100 µm. Th, helper T cell
a, A biplot of principal components from k-means five-cluster analysis for a total of 353 TLSs with six variables consisting of Th, B cells, FDCs, CTL, GC-B cells, and macrophages. b, Parallel coordinate plots displaying the normalized values of the six variables. The five clusters were separated using k-means cluster analysis. A colored thin line represents a TLS. A gray colored bold line shows the mean value of those variables. c, Representative images of each TLS cluster. Slides were stained with CD3 (yellow), CD20 (purple), CD8 (green), FDC (white), CD68 (pink), Bcl-6 (red), and DAPI (blue). Scale bar, 100 µm. d, Stacked bar charts representing the proportions (%) of the five TLS types per all TLSs in each patient without (n = 47) and with (n = 11) disease recurrence. The horizontal label represents the number of TLSs per patients’ slides. e, Comparisons of the proportions of five types of TLSs between patients without and with disease recurrence (not recurrence, n = 47; recurrence, n = 11). P values were calculated by the Wilcoxon rank-sum test. Dots indicate the value of each patient. Box plots show the median, first and third quartiles, and whiskers extend to 1.5 times the interquartile range of the patient groups. Th, helper T cell; GC, germinal center; TLS, tertiary lymphoid structure; CTL, cytotoxic T lymphocyte; FDC, follicular dendritic cell; No rec, patients without recurrence; Rec, patients with recurrence
Supplemental material